“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...

Adults as young as 50 may now qualify for an respiratory synctial virus vaccine if they have certain health conditions.

The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...

Failure to recognize and resolve problems in an honest and evidence-based manner is the root cause of increasing vaccine ...

Kennedy selected a new team of medical professionals and scientists who are highly qualified and dedicated to public health.

The update covers the safety and appropriate timing of vaccinations, screening for osteoporosis, cervical cancer, skin cancer ...

GSK plc GSK announced that the FDA has accepted its regulatory filing seeking to expand the use of its RSV vaccine, Arexvy, in adults under 50 who are at a higher risk of the disease. A final decision ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50, down from 60, following ...

Vaccines do much more than prevent specific diseases — their side benefits save children's lives around the world ...

If I have sounded like a broken record these past months, it is because these developments in American public health are as ...